Nasdaq:AMGN
AMGEN INC
Amgen is a premier global biotech innovator delivering breakthrough treatments for cancer, immunology, and cardiovascular diseases with a strong commercial pipeline.
Key Metrics
Investment Thesis
Bull Case
Investors may favor Amgen due to its diversified portfolio of high-value assets that provide stable cash flows to fund continued R&D and potential M&A activity. The recent surge in net income suggests the company is overcoming prior volatility, positioning it well for long-term value creation as new therapies enter commercialization.
Bear Case
The company carries a substantial debt load of $50B plus $4.6B in current maturities, which could constrain flexibility during periods of tighter credit markets or rising interest rates. Recent increases in operating expenses and amortization indicate heavy investment in sustaining assets that may not yet translate into proportional revenue growth.
About AMGEN INC
Amgen Inc. is a leading global biotechnology company focused on discovering, developing, manufacturing, and delivering innovative medicines to patients with serious diseases, primarily serving the United States, Europe, Asia-Pacific, and Latin America. The company's portfolio centers on oncology, immunology, cardiovascular disease, inflammation, nephrology, and bone health, anchored by blockbuster products like Enbrel, Prolia, and Keytruda. With a robust balance sheet and a history of consistent revenue growth, Amgen leverages its extensive R&D capabilities to bring life-saving therapies to market.
Analysis
Management Discussion
Amgen reported a significant rebound in profitability with net profit reaching $7.71B in 2025, up from $4.09B the previous year, indicating improved operational efficiency or favorable product mix shifts. Revenue growth accelerated to $36.75B, outpacing the prior year's pace and demonstrating strong demand for its oncology and immunology therapies despite macroeconomic headwinds.
Industry Overview
The biotechnology sector is characterized by high R&D costs, rigorous regulatory oversight, and rapid technological advancement driven by precision medicine and immunotherapy breakthroughs. Companies in this space must continuously innovate to extend product lifecycles and navigate complex reimbursement landscapes while competing against large pharmaceutical giants.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $26.32B | $28.19B | $33.42B | $36.75B |
| Cost of Revenue | $6.41B | $8.45B | $12.86B | $12.04B |
| Gross Profit | $19.92B | $19.74B | $20.57B | $24.71B |
| Operating Expenses | $10.35B | $11.84B | $13.31B | $15.63B |
| Operating Income | $9.57B | $7.90B | $7.26B | $9.08B |
| G&A | $5.41B | $6.18B | $7.10B | $7.05B |
| Stock-Based Comp | $401.0M | $431.0M | $530.0M | $494.0M |
| D&A | $3.42B | $4.07B | $5.59B | $5.17B |
| Depreciation | $661.0M | $685.0M | $694.0M | $763.0M |
| Amortization | $2.60B | $3.20B | $4.80B | $4.30B |
| Other OpEx | $4.94B | $5.66B | $6.21B | $8.58B |
| Non-Operating Income | $-2.22B | $-42.0M | $-2.65B | $-104.0M |
| Interest Income | — | $1.20B | $510.0M | $408.0M |
| Pre-Tax Income | $7.35B | $7.86B | $4.61B | $8.98B |
| Income Tax | $794.0M | $1.14B | $519.0M | $1.26B |
| Continuing Ops | $6.55B | $6.72B | $4.09B | $7.71B |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $6.55B | $6.72B | $4.09B | $7.71B |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $6.55B | $6.72B | $4.09B | $7.71B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $22.19B | $30.33B | $29.03B | $29.06B |
| Cash & Equivalents | $7.63B | $10.94B | $11.97B | $9.13B |
| Accounts Receivable | $5.56B | $7.27B | $6.78B | $9.57B |
| Inventory | $4.93B | $9.52B | $7.00B | $6.22B |
| Other Current Assets | $4.06B | $2.60B | $3.28B | $4.13B |
| Long-Term Assets | $42.94B | $66.82B | $62.81B | $61.53B |
| PP&E (Net) | $5.43B | $5.94B | $6.54B | $7.91B |
| Intangibles | $16.08B | $32.64B | $27.70B | $22.28B |
| Goodwill | $15.53B | $18.63B | $18.64B | $18.68B |
| Operating Leases | $579.0M | $651.0M | $557.0M | $602.0M |
| Other LT Assets | $5.32B | $8.96B | $9.37B | $12.06B |
| Total Assets | $65.12B | $97.15B | $91.84B | $90.59B |
| Current Liabilities | $15.69B | $18.39B | $23.10B | $25.49B |
| Accounts Payable | $1.57B | $1.59B | $1.91B | $2.37B |
| Current Debt | $1.59B | $1.44B | $3.55B | $4.60B |
| Current Leases | $156.0M | $119.0M | $107.0M | $135.0M |
| Taxes Payable | $1.20B | $1.66B | $2.58B | $379.0M |
| Other Current Liab | $-2.49B | $-2.99B | $-3.97B | $-1.87B |
| Long-Term Liabilities | $45.77B | $72.53B | $62.86B | $56.44B |
| Long-Term Debt | $37.35B | $63.17B | $56.55B | $50.01B |
| LT Operating Leases | $539.0M | $691.0M | $673.0M | $696.0M |
| Other LT Liab | $7.88B | $8.67B | $5.64B | $5.74B |
| Total Liabilities | $61.46B | $90.92B | $85.96B | $81.93B |
| Shareholders' Equity | $3.66B | $6.23B | $5.88B | $8.66B |
| Paid-In Capital | $32.51B | $33.07B | $33.53B | $34.02B |
| Retained Earnings | $-28.62B | $-26.55B | $-27.59B | $-25.11B |
| AOCI | $-231.0M | $-289.0M | $-66.0M | $-258.0M |
| Total L&E | $65.12B | $97.15B | $91.84B | $90.59B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $6.55B | $6.72B | $4.09B | $7.71B |
| Non-Cash Adjustments | $1.67B | $1.37B | $10.38B | $487.0M |
| Working Capital Changes | $1.50B | $386.0M | $-2.98B | $1.76B |
| Cash from Operations | $9.72B | $8.47B | $11.49B | $9.96B |
| Capital Expenditures | $936.0M | $1.11B | $1.10B | $1.86B |
| Cash from Investing | $-6.04B | $-26.20B | $-1.05B | $-1.94B |
| Debt Issuances | $6.92B | $27.78B | $0 | $0 |
| Debt Repayments | $0 | $1.45B | $3.60B | $5.00B |
| Share Buybacks | $6.36B | $0 | $200.0M | $0 |
| Dividends Paid | $4.20B | $4.56B | $4.83B | $5.12B |
| Cash from Financing | $-4.04B | $21.05B | $-9.41B | $-10.86B |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-360.0M | $3.31B | $1.03B | $-2.84B |
| Beginning Cash | $7.99B | $7.63B | $10.94B | $11.97B |
| Ending Cash | $7.63B | $10.94B | $11.97B | $9.13B |
Frequently Asked Questions
How does AMGEN INC make money?
The company generates revenue primarily through the sale of licensed pharmaceutical products such as Enbrel, Prolia, Xgeva, and Keytruda across its core therapeutic areas including oncology, inflammation, nephrology, and bone health. Revenue streams are further diversified by licensing activities where Amgen develops and manufactures products for partner companies while retaining a share of the sales.
What are the main risks for AMGN?
Potential approval delays or adverse safety findings from regulatory bodies like the FDA could impact new product launches and existing portfolio performance. The biotechnology industry faces intense patent cliffs where key products lose exclusivity, leading to generic competition and revenue erosion. High levels of debt relative to equity require careful management as interest rates fluctuate and cash flow dynamics shift.
What is AMGN's competitive advantage?
Amgen possesses deep proprietary science and an extensive pipeline of late-stage assets that provide a significant barrier to entry in crowded therapeutic markets. The company benefits from a strong commercial infrastructure with broad global reach and established market access, complemented by a proven track record of successful licensing agreements that de-risk development.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.